Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Camargo Speaks at Israeli Drug Development Seminar | Contract Pharma

What are you searching for?

Sign in
Breaking News

Camargo Speaks at Israeli Drug Development Seminar

Ken Phelps addresses opportunities through 505(b)(2)

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

During a recent drug development seminar held in Tel Aviv with a group of 40 C-level executives, Ken Phelps, president and chief executive officer of Camargo Pharmaceutical Services, addressed Israeli pharma executives on the 505(b)(2) development process as an important tool that can reduce costs and shorten the timeline for approval of new drugs.
 
“Israel is known for innovation, and Israeli developers offer a wide range of drug candidates with good market potential and an opportunity to gain FDA approval through 505(b)(2),” said Mr. Phelps. He added that development under 505(b)(2) is ideal for drugs making a change from a previously approved drug because it allows utilizing selected data from studies in the public domain.
 
“For new indications, drugs that enhance some aspect of an existing drug, drugs with dosage changes or new active ingredients, prodrugs, combination drugs or drug-device combinations, 505(b)(2) can be an attractive alternative,” Mr. Phelps said.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics